Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Revolution Medicines Inc

Healthcare US RVMD

155.69USD
-0.3(0.19%)

Last update at 2026-06-04T20:20:00Z

Day Range

154.60159.34
LowHigh

52 Week Range

15.4440.63
LowHigh

Fundamentals

  • Previous Close 155.99
  • Market Cap6252.97M
  • Volume2608534
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-522.04198M
  • Revenue TTM4.57M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -217.69300M
  • Diluted EPS TTM-3.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -249.12500M -187.09100M -108.53000M -52.03700M -41.78900M
Minority interest - - - - -
Net income -248.70500M -179.77100M -108.15900M -47.66400M -41.78900M
Selling general administrative 40.59M 30.45M 21.43M 12.41M 9.41M
Selling and marketing expenses - - - - -
Gross profit 35.38M 29.39M 42.98M 50.04M 20.16M
Reconciled depreciation 9.66M 7.33M 6.54M 3.34M 1.76M
Ebit -258.27900M -188.00800M -110.69700M -54.12000M -41.67300M
Ebitda -249.12500M -187.07900M -108.45900M -48.58900M -39.90900M
Depreciation and amortization 9.15M 0.93M 2.24M 5.53M 1.76M
Non operating income net other - 0.93M 2.24M - -
Operating income -258.27900M -188.00800M -110.69700M -54.12000M -40.32900M
Other operating expenses 293.66M 217.40M 153.68M 104.16M 60.49M
Interest expense -9.65600M 0.01M 0.07M 0.11M 0.12M
Tax provision -0.42000M 0.00000M -0.37100M -4.37300M -
Interest income 9.15M 0.93M 2.24M 2.19M 0.78M
Net interest income 9.15M 0.92M 2.17M 2.08M 0.66M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.42000M -7.32000M -0.37100M -4.37300M -1.34400M
Total revenue 35.38M 29.39M 42.98M 50.04M 20.16M
Total operating expenses 293.66M 217.40M 153.68M 104.16M 60.49M
Cost of revenue - - - - 50.28M
Total other income expense net 9.15M 0.92M 2.17M 2.08M -2.12100M
Discontinued operations - - - - -
Net income from continuing ops -248.70500M -187.09100M -108.15900M -47.66400M -41.78900M
Net income applicable to common shares -248.70500M -187.09100M -110.37800M -61.90200M -48.82000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2088.59M 811.93M 737.99M 567.40M 220.53M
Intangible assets 57.74M 58.81M 59.88M 60.95M 62.01M
Earning assets - - - - -
Other current assets 25.07M 10.57M 6.79M 6.99M 2.49M
Total liab 262.40M 126.74M 135.42M 92.72M 67.99M
Total stockholder equity 1826.19M 685.19M 602.57M 474.68M 152.53M
Deferred long term liab - 0.60M 0.50M 7.44M 2.10M
Other current liab 74.69M 29.45M -20.27100M 10.30M 14.36M
Common stock 0.02M 0.00900M 0.00800M 0.00700M -
Capital stock 0.02M 0.00900M 0.00800M 0.00700M 305.11M
Retained earnings -1137.70800M -701.34100M -452.63600M -265.54500M -157.38600M
Other liab - 7.33M 14.65M 16.56M 24.94M
Good will 14.61M 14.61M 14.61M 14.61M 14.61M
Other assets 0.00000M 4.59M 2.50M 1.39M 2.78M
Cash 696.15M 161.41M 108.50M 104.27M 16.66M
Cash and equivalents - - - - -
Total current liabilities 143.85M 61.98M 18.93M 47.18M 43.05M
Current deferred revenue - 4.46M 18.93M 20.59M 17.12M
Net debt -608.20400M -97.20700M -41.86400M -71.60400M -16.48700M
Short term debt 7.37M 6.77M 6.21M 3.67M 0.17M
Short long term debt - - - - -
Short long term debt total 87.94M 64.20M 66.63M 32.66M 0.17M
Other stockholder equity 2963.34M 1388.30M 317.58M 172.70M 4.74M
Property plant equipment - 73.74M 71.24M 8.90M 7.15M
Total current assets 1879.28M 660.18M 577.05M 454.12M 133.98M
Long term investments - - - - -
Net tangible assets - 611.77M 528.08M 399.12M -229.19500M
Short term investments 1156.81M 483.53M 468.56M 336.47M 106.10M
Net receivables 1.25M 4.67M 5.93M 6.39M 8.74M
Long term debt - - - - -
Inventory 0.00000M - -12.71900M - -
Accounts payable 61.79M 21.31M 14.06M 12.61M 11.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.54M -1.78000M -0.37600M 0.12M 0.07M
Additional paid in capital - - - - -
Common stock total equity - - 0.00800M 0.00700M -
Preferred stock total equity - - - - -
Retained earnings total equity - - -452.63600M -265.54500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.03M 4.59M 15.21M 1.39M 2.78M
Deferred long term asset charges - - - - -
Non current assets total 209.31M 151.75M 160.93M 113.28M 86.55M
Capital lease obligations 87.94M 64.20M 66.63M 32.66M 0.17M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -24.11600M -135.58900M -231.30000M -105.57600M -1.33900M
Change to liabilities -7.60300M 0.58M -5.92300M -12.50100M 44.61M
Total cashflows from investing activities -24.11600M -142.11700M -234.23300M -101.96900M -1.33900M
Net borrowings - - - - -
Total cash from financing activities 301.43M 294.18M 422.78M 98.66M 60.85M
Change to operating activities -7.14200M 7.68M 0.68M 5.11M 0.76M
Net income -248.70500M -187.09100M -108.15900M -47.66400M -41.78900M
Change in cash 52.91M 4.88M 88.48M -52.92700M 60.72M
Begin period cash flow 110.23M 105.35M 16.87M 69.80M 9.08M
End period cash flow 163.15M 110.23M 105.35M 16.87M 69.80M
Total cash from operating activities -224.40100M -147.18000M -100.06400M -49.61600M 1.21M
Issuance of capital stock 298.05M 291.24M 420.07M 100.03M 60.56M
Depreciation 9.66M 7.33M 6.54M 3.34M 1.76M
Other cashflows from investing activities - - - -99.38000M 0.16M
Dividends paid - - - - -
Change to inventory - 7.68M - - -
Change to account receivables 1.26M 0.46M 2.34M -1.43400M -7.30300M
Sale purchase of stock 1.86M 1.88M 0.83M 100.26M 60.85M
Other cashflows from financing activities 1.52M 1.06M 1.88M -1.37000M 60.43M
Change to netincome 28.14M 23.86M 8.51M 3.53M 3.18M
Capital expenditures 10.82M 6.53M 2.93M 2.59M 1.50M
Change receivables - 0.46M 2.34M - -
Cash flows other operating - 0.17M -1.48400M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 4.88M 88.48M - -
Change in working capital -13.48900M 8.72M -8.30400M -8.82800M 38.06M
Stock based compensation 31.20M 20.72M 8.89M 3.16M 0.85M
Other non cash items -2.64000M 3.13M 1.34M 4.75M 2.12M
Free cash flow -235.21700M -153.70800M -102.99700M -52.20500M -0.28600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RVMD
Revolution Medicines Inc		 -0.3 0.19% 155.69 - - 512.99 3.25 360.71 -9.7077
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc

700 Saginaw Drive, Redwood City, CA, United States, 94063

Key Executives

Name Title Year Born
Dr. Mark A. Goldsmith Ph.D. CEO, Pres & Chairman 1962
Mr. Jack Anders Chief Financial Officer 1977
Ms. Margaret A. Horn J.D. Chief Operating Officer 1963
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. Pres of R&D 1961
Ms. Xiaolin Wang Exec. VP of Clinical Devel. 1971
Dr. Martin D. Burke M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Michael A. Fischbach Ph.D. Academic Co-Founder & Member of Scientific Advisory Board 1981
Dr. Kevan M. Shokat Ph.D. Academic Co-Founder & Member of Scientific Advisory Board NA
Mr. David L. Pompliano Ph.D. Founding Chief Scientific Officer NA
Mr. Walter Reiher Ph.D. Chief Information Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.